KaloBios was an early entrant in 2013’s boom of biotech IPOs, touting its development technology as a springboard for high-quality antibodies. A year later, that promise hasn’t come to fruition, and partner Sanofi is walking away from an antibacterial program for which the company had high hopes.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]